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Aortic remodeling after endovascular repair of
acute complicated type B aortic dissection
Mark F. Conrad, MD, Robert S. Crawford, MD, Christopher J. Kwolek, MD, David C. Brewster, MD,
Thomas J. Brady, MD, and Richard P. Cambria, MD, Boston, Mass
Objective: The role of thoracic endovascular aortic repair (TEVAR) in the management of acute type B aortic dissection
remains undefined. Entry tear coverage during the acute phase is an appealing method to treat acute complications, and
by inducing false lumen thrombosis, might also prevent late aneurysm formation. This study evaluated structural changes
by serial computed tomography (CT) in the thoracic aorta after TEVAR performed for acute complicated aortic
dissection.
Methods: Between August 2005 and October 2007, 33 patients with complicated acute type B aortic dissection were
treated with TEVAR (19 from a prospective industry sponsored trial, 14 from our institution). CT images obtained
preprocedurally (PP), at 1 month (1M), and 1 year (1Y) were evaluated for each patient. Four patients with no
postprocedural imaging were excluded. The largest diameters of the thoracic aorta, dissection true lumen, and false lumen
were recorded at each time point. Canges in total aortic and true and false lumen diameters were evaluated using a mixed
effect analysis of variance model of repeated measures.
Results: The average age was 58 years (range, 38-87 years); 26 (81%) were male. Indications for TEVAR included
malperfusion syndrome in 17 (53%), refractory hypertension in 14 (44%), impending rupture in 12 (28%), and refractory
pain in 14 (44%); 19 (59%) had more than one indication. The average length of aorta covered was 19.5 cm (range,
10-29.3 cm). The maximum aortic diameter decreased over time (P .04) and averaged 39.9 (PP), 41.3 (1M), and 34.8
mm (1Y). The true lumen diameter increased over time (P .02) and averaged 23.7 (PP), 29.0 (1M), and 31.1 mm (1Y).
The false lumen diameter decreased (P .046) and averaged 19.5 (PP), 12.1 (1M), and 9.6 mm (1Y). Partial or complete
thrombosis of the false lumen along the stented segment of aorta was recorded in 87% (PP), 93% (1M), and 88% (1Y).
Conclusions: TEVAR of acute complicated aortic dissection appears to promote early aortic remodeling. Nearly 90% of
patients maintained at least partial false lumen thrombosis at 1 year. Because continued false lumen patency correlates
strongly with late aneurysm formation, such favorable remodeling is considered a surrogate for prevention of late
aneurysm, but longer follow-up is required. (J Vasc Surg 2009;50:510-7.)Acute aortic dissection (AD) is the most common
catastrophic event affecting the aorta, with an incidence
exceeding that of ruptured abdominal aortic aneurysm.
Indeed, Khan et al1 predicted that the mortality rate of
acute AD left untreated will exceed 22.7% 6 hours, 50%
24 hours, and 68% 1 week, with death from dissections
of the descending thoracic aortic caused by aortic rupture
or, more commonly, end organ compromise due to ob-
struction of visceral or extremity vessels (malperfusion syn-
drome).2,3 The morbidity and mortality for complicated
Stanford type B AD (dissection distal to the origin of the
left subclavian artery) greatly exceeds that of type B AD
without such compromise (ie, those treated medically).4,5
Indeed, 85% to 90% of patients who present with uncom-
plicated type B AD are discharged with medical therapy
alone, whereas 50% of patients with complicated AD are
at risk of dying and require an emergency intervention of
some kind.6
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510Traditionally, patients who present with type B AD
complicated by impending rupture or a malperfusion syn-
drome were treated with open graft replacement of the
proximal descending thoracic aorta, resulting in a mortality
rate of 6% to 69% in several large series.7-10 Because of the
high morbidity and mortality associated with open surgery
in the acute phase, medical management centered around
blood pressure control is the accepted standard of care for
patients with uncomplicated acute type B AD. Unfortu-
nately, aneurysmal dilation of the false lumen will develop
in 25% to 40% of medically managed patients5 years.11-13
In 1999 the endovascular treatment of complicated
acute type B dissections (TEVAR) with stent graft coverage
of the proximal entry tear was described in two sentinel
reports.14,15 This approach has successfully decreased the
perioperative mortality rate in such patients, but few data
exist regarding the long-term aortic structural changes after
TEVAR.16,17 This study evaluated structural changes (aor-
tic remodeling) in the thoracic aorta after TEVAR per-
formed for acute complicated type B dissection.
METHODS
The study population included 33 patients who under-
went TEVAR for complicated acute Stanford type B AD
between August 2005 and October 2007. Of these, 19
patients were treated as part of a prospective, multicenter
industry-sponsored trial (TAG-0401), and the remaining
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graphic and clinical factors were collected for each patient,
as were 30-day and 1-year mortality data. Hypertension,
chronic obstructive pulmonary disease, and history of
stroke were considered present if they were part of the
patient’s history regardless of current medications or past
interventions. Renal insufficiency was defined as a baseline
creatinine 1.5 mg/dL, and patients were considered to
have coronary disease even if they had undergone revascu-
larization in the past. Clinical end points for the study
include mortality and anatomic follow-up based on serial
computed tomography (CT) scanning.
Massachusetts General Hospital cohort. During the
study interval, 16 patients underwent TEVAR for acute
complicated type B AD at Massachusetts General Hospital
(MGH). Two of these patients were enrolled in the TAG-
0401 study and the remaining 14 comprise the MGH
cohort. All patients included in the MGH cohort met
inclusion criteria for the TAG-0401 study. Data for these
patients were collected prospectively but reviewed in a
retrospective fashion for this study. Patients were included
if they underwent TEVAR for type B AD complicated by
malperfusion with end-organ ischemia, hypertension re-
fractory to medical therapy, aortic rupture or impending
rupture, or persistent pain despite adequate blood pressure
control. These conditions were chosen because they were
the inclusion criteria for the TAG-0401 trial.
TEVAR was performed in all patients 14 days of
onset of symptoms so that all AD were truly acute at the
time of therapy. All patients underwent preoperative CT
scanning in preparation of TEVAR, and our follow-up
protocol included CT scanning at 4 to 6 weeks and then at
6 months and 1 year after the procedure.
Digital diameter measurements of the descending tho-
racic aorta between the left subclavian artery to the celiac
access were obtained at each scanning time point using our
in-house image viewing software (Amicus Inc, Austin,
Tex). These included the largest total descending thoracic
aortic diameter, the largest true lumen diameter, and the
largest false lumen diameter. Every attempt was made to
obtain a true diameter measurement, and aortic angulation
was taken into account when determining the location for
each measurement; however, software that allows auto-
matic centerline measurements was not used. Each individ-
ual measurement was not necessarily taken at the same level
in the aorta so that addition of the maximum true and false
lumen diameters could result in a number that exceeds the
largest total aortic diameter measured.
In addition to diameter evaluation, the false lumen
along the treated segment of aorta was evaluated for the
presence of thrombosis and was characterized as none and
partial/complete. This method of anatomic evaluation was
used to conform with the TAG-0401 protocol. The MGH
Institutional Review Board (IRB) approved this protocol
and individual consent was waived.
TAG-0401. The Gore TAG-0401 study is a prospec-
tive, nonrandomized, literature controlled, multicenter
trial of TEVAR of complex aortic pathologies that enrolledpatients between August 2005 and February 2007. The
study has three arms, and the 19 patients enrolled in the
acute complicated type B AD arm are included in this
patient cohort. As part of the inclusion criteria, all patients
patients were considered candidates for open repair at the
time that they underwent TEVAR. The 19 patients in this
arm of the study were treated at six institutions, including
two patients from MGH. All patients presented with acute
complicated type B AD, as detailed in the MGH cohort.
Patients underwent imaging with noncontrast and
contrast-enhanced, thin-sliced (range, 1-2.5 mm) spiral CT
with multi-planar reconstruction of the chest, abdomen,
and pelvis to confirm study eligibility and for preprocedural
planning. Patients were then monitored with serial CT
scans at 30 days, 6 months, 1 year, and yearly afterward,
with planned completion at 5 years. Additional imaging
studies were performed at the discretion of the treating
physician.
Clinical data were reported by individual centers that
were monitored by sponsor representatives. Image analysis,
including serial diameter measurement, was performed by
the imaging services department of the sponsor. The pro-
tocol and procedures of the TAG-0401 trial were approved
by the United States Food and Drug Administration (FDA)
and the individual IRBs of each participating center. Pa-
tients, or their surrogates, signed a research informed con-
sent before participation in this study.
MGH operative details. TEVAR at MGH is per-
formed in an endovascular operating suite equipped with
digital subtraction angiography by participating vascular
surgeons. General anesthesia was used for all procedures,
and spinal drains were placed at the discretion of the
operating surgeon. Stent grafts were introduced into the
aorta through a cutdown on the common femoral artery.
Iliac conduits were used in patients with unsuitable iliac
vessels for stent graft delivery (2 patients in the MGH
cohort).
Several technical components of the procedure should
be detailed here. All patients underwent seal of the proxi-
mal entry tear at the level of the left subclavian artery with
the Gore TAG covered stent graft (W.L. Gore and Associ-
ates, Flagstaff, Ariz). True lumen access was obtained from
a brachial or femoral approach. Because the tear in the type
B dissection is distal to the left subclavian artery, rapid true
lumen access is easily obtained through a right transbrachial
approach. In the MGH cohort, intravascular ultrasound
(IVUS) imaging was performed from the aortic arch to the
iliac vessels to define the relationship of the dissection flap
to the visceral and renal arteries and confirm true lumen
position at the level of the left subclavian artery (Fig 1).
Angiography was performed sparingly and limited to
hand injections of selected branch arteries to prove that the
catheter/wire was beyond the dissection and in the true
lumen of the healthy artery. This practice limits the contrast
load during the procedure, thus avoiding further insult to
the kidneys. In addition, power injection in the true lumen
of the dissected aorta may give the false impression of
adequate perfusion to branch vessels compromised by
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was confirmed by the presence of a gradient between the
aortic root and branch (not aorta) end-hole catheter pres-
sures, as described by Barnes et al.18
Endografts were deployed proximally with or without
coverage of the left subclavian artery to obtain an adequate
seal of the entry tear. Most patients were treated with one
endograft prosthesis; additional pieces were placed only
Fig 1. Intravascular ultrasound (IVUS) evaluation of the thoracic
aorta. A, The true lumen (TL) is compressed and free floating in
the thoracic aorta, and the false lumen (FL) is larger than the TL.
IVUS has been used to confirm that the wire is in the true lumen.
B, The relationship of the dissection flap/true lumen (TL) to the
celiac artery is shown.when the initial graft did not produce the desired result ofcoverage of the entry tear and expansion of the true lumen
as determined by intraoperative IVUS imaging and angiog-
raphy (Fig 2). Bare metal stents were placed at the origin of
the visceral and renal vessels when necessary to ensure
adequate end-organ blood flow.
Statistical analysis. Descriptive statistics were per-
formed on the available variables for the entire study cohort
of 33 patients. Differences in aortic diameter measurements
over time were determined using a mixed-effect analysis of
variance model of repeated measures. A value of P  .05
was considered significant.
RESULTS
The study cohort comprised 33 patients. Available
demographic and clinical factors are detailed in Table I.
The two groups were similar except for prevelance coronary
disease, which was present only in the MGH cohort. All
patients underwent TEVAR for complications related to
their acute dissection, as summarized in Table II. The
average length of aorta covered was 19.5 cm (range, 10-
29.3 cm).
Four patients died (3 from TAG-0401 and 1 from
MGH) for a 30-day mortality of 12%. Two patients died of
complications related to periprocedural strokes, and one
died of a postprocedural aortic rupture. The third patient’s
recovery was complicated by respiratory failure and flaccid
lower extremity paralysis and the family withdrew care.
Two patients (6%) presented with lower extremity weak-
ness after TEVAR. The first was the patient who died, and
the second experienced transient weakness that resolved
with spinal drainage and hypertensive therapy. In-hospital
complications are summarized in Table III. During the
1-year follow-up, an additional four patients died for a total
1-year mortality of eight (24%).
Complete radiographic follow-up was available on 21
of the 25 patients who remained alive at 1 year. The average
maximum aortic diameter showed a slight increase from the
preprocedural scan to the 1 month follow-up, but then
decreased by 1 year leading to a significant decrease over
time, respectively, of 39.9, 41.3, and 34.8 mm (P  .04;
Fig 3). The average maximum diameter in mm of the true
lumen significantly increased over time from 23.7 postpro-
ceduraly to 29 at 1 month to 31.1 at 1 year (P  .004;
Fig 4). The average maximum false lumen diameter in mm
significantly decreased, respectively, from 19.5 postproce-
duraly to 12.1 at 1 month to 9.6 at 1 year (P  .0001;
Fig 5).
The initial diameter of the false lumen was not predic-
tive of change in aortic diameter at 1 year. Partial or
complete thrombosis of the false lumen along the treated
aortic segment was recorded in 87% of patients who had an
immediate postprocedural scan, in 93% at 1 month, and in
88% at 1 year. False lumen expansion occurred in four
patients during follow-up, and two of these had no throm-
bosis of the false lumen.
he tr
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The optimal management of acute type B AD remains a
topic of ongoing investigation. The ability of TEVAR to
accomplish the anatomic goal of surgical graft replacement
of the proximal entry tear has engendered a new era in the
Fig 2. Computed tomography angiogram of the aorta.A
shows compressed true lumen. B, Three-dimensional re
C,Axial image of dissection shows compressed true lume
D, Axial image of thoracic aorta in same patient after end
the false lumen. E, Axial image shows the celiac axis with
in same patient after placement of proximal endograft. Ttreatment of acute type B AD. Treatment options haveevolved first from the precept that medical therapy pro-
duced equivalent outcomes to surgical resection of the
entry tear.19 Next, it has been amply demonstrated that
uncomplicated patients who can be medically treated
have favorable early outcomes.4,5 Finally, and as intu-
ree-dimensional reconstruction of acute aortic dissection
truction shows dissection after placement of endograft.
is completely detached from the surrounding adventitia.
fting shows expansion of the true lumen with no flow in
pressed true lumen. F, Axial image shows the celiac axis




comitively expected, patients with secondary complications
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plicated cases.3,20,21
Despite advances in anesthesia and operative tech-
niques, death after open repair of the descending aorta
for patients with branch vessel compromise remains
high.7-10,22 A recent review of 476 patients with acute type
B AD from the International Registry of Acute Aortic
Dissection (IRAD) database showed that 82 (17.2%) were
treated surgically with descending aortic replacement
(70%), partial arch replacement (21%), or total arch replace-
ment (8%).10 The perioperative mortality rate of this cohort
was 29.3%, with the highest death rate occurring in patients
Table I. Demographic and clinical data for 33 patients
undergoing thoracic endovascular aneurysm repair for








Male gender 26 (79) 16 (84) 10 (71) .37
White race 25 (76) 15 (79) 10 (71) .62
Hypertension 31 (94) 18 (95) 13 (93) .82
COPD 6 (18) 3 (16) 3 (21) .68
CAD 4 (12) 0 (0) 4 (29) .01a
History of stroke 5 (15) 3 (16) 2 (14) .91
Renal insufficiency 6 (18) 3 (16) 3 (21) .68
Age, y 58 58.9 58.1 .88
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ease; MGH, Massachusetts General Hospital.
aSignificance.
Table II. Indications for thoracic endovascular aneurysm
repair in 33 patients
Indication No. (%)
Malperfusion syndrome 17 (53)
Refractory hypertension 14 (44)
Impending rupture 12 (28)
Uncontrolled pain 14 (44)
1 indication 19 (59)
Table III. Complications after thoracic endovascular
aneurysm repair for acute type B dissection
Complication No. (%)
1 major event 25 (76)
Ruptured aorta 2 (6)
Endoleak 3 (9)
Bleeding 2 (6)
Additional dissection 3 (9)
Cardiac 5 (15)
Pulmonary 8 (24)
Renal insufficiency 4 (12)
Cerebrovascular 4 (12)
Deep vein thrombosis/pulmonary embolus 2 (6)
Spinal cord ischemia 1 (3%)
Groin hematoma 2 (6%)who required operation 24 hours of presentation. The30-day mortality rate of 12% in the current study compares
favorably with this contemporary series of open thoracic
aortic replacement. An additional IRAD study showed that
the in-hospital mortality was 30.8% in patients who under-
went surgical therapy compared with 9.1% for endovascular
repair (P  .001), making TEVAR an attractive option
when possible.23
Early reports of TEVAR have been favorable for com-
plicated acute type B AD.14-16 From a practical perspective,
however, stent graft repair of AD in the United States has
only been available since April 2005, coincident with initial
FDA approval of a commercially available thoracic stent
graft. To date, the application of available TEVAR devices
in AD outside of clinical trials constitutes off-label usage
because such devices are currently only FDA-approved in
the United States for treatment of degenerative thoracic
aneurysms. Although the low mortality rate seen with
initial reports has made TEVAR the first line of therapy at
Fig 3. Changes in maximal aortic diameter were significantly
different over time. (P  .04).
Fig 4. Changes in maximal true lumen diameter were signifi-
cantly different over time (P  .004).
Fig 5. Changes in maximal false lumen diameter were signifi-
cantly different over time (P  .0001).MGH for patients with complicated acute type B ADs, the
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unclear.
To potentially clarify (although it has not) the role of
stent graft treatment of type B AD, the Investigation of
Stent-grafts in Aortic Dissection (INSTEAD) trial was de-
signed as a prospective, randomized, multicenter trial per-
formed in Europe that compared stent grafting with med-
ical therapy for the treatment of chronic uncomplicated
type B AD. All patients were randomized 2 weeks after
symptom onset; thus, patients with early complications—
those who would most likely benefit from endovascular
therapy—were essentially subtracted from the study co-
hort. Not surprisingly, the investigators found no differ-
ence in 30-day mortality between the two groups. In fact,
the 1-year survival probability was 91% in TEVAR patients
vs 97% with medical treatment (P  .16), reflecting a
periprocedural mortality rate of 3%.
The encouraging data reported in this trial were with
respect to aortic remodeling, which may be considered a
surrogate for prevention of late aneurysm formation. To
wit,90% of patients in the stent graft cohort experienced
false lumen thrombosis at 1 year, which was significantly
higher than the medically treated group.24 This number
was similar to our results of 88% of patients with partial or
complete false lumen thrombosis at 1 year.
Although most late deaths are related to comorbid
conditions, subsequent complications such as aneurysmal
development and late rupture have been estimated to occur
in 20% to 50% of patients.25-27 The identification of a
higher false lumen thrombosis rate in the TEVAR cohort of
the INSTEAD trial is promising, because persistent false
lumen patency is an independent risk factor for aneurysmal
degeneration of medically treated dissections.14,28-32 In-
deed, Sueyoshi et al33 showed that a patent false lumen will
enlarge 3.3 mm/year even in stable, uncomplicated cases.
In a review of the IRAD data, Tsai et al32 showed that
partial thrombosis of the false lumen in medically treated
patients is an independent predictor of death after dis-
charge, with partial thrombosis having the worst results at
31.6% compared with 13.7% for patent and 22.6% for
complete thrombosis.32 The proposed mechanism of this is
that formation of thrombus may occlude the distal outflow
fenestrations, leading to a significant increase in the mean
arterial and diastolic pressure in the false lumen compared
with that of a patent lumen with adequate outflow or one
that is totally thrombosed.32
This model was based on the assumption that partial
false lumen thrombosis occurs in the distal portion of the
dissection with continued pressurized perfusion proxi-
mally. In theory, TEVAR should address this problem,
because coverage of the proximal entry tear promotes prox-
imal thrombosis so that persistent flow through the patent
distal false lumen should be associated with lower pressures.
Thus, the concept of inducing false lumen thrombosis by
sealing the aortic tear with an aortic endograft has the
potential to reduce early and late complications of type B
AD, and in our study, the false lumen was at least partially
thrombosed in 88% of patients at 1 year.The goals of TEVAR for acute type B AD include
coverage of the proximal entry tear, expansion of the true
lumen with restoration of flow to the visceral vessels, and
obliteration of false lumen flow with subsequent complete
thrombosis. This concept of false lumen obliteration and
true lumen expansion has been termed aortic remodeling
and stabilization of the aorta. When these components of
therapy are successful, aortic remodeling should occur,
with subsequent prevention of future aneurysmal degener-
ation of the outer wall of the false lumen. Indeed, the false
lumen measurements in our study decreased over time and
the true lumen increased, resulting in early remodeling as
evidenced by the decrease in the thoracic aortic diameter.
Thus, although there has been appropriate emphasis on
TEVAR to treat acute complications, our data and that of
others indicate that it also has great promise to prevent the
principle late complication of aneurysm formation.16,34
Several recent studies have looked at early aortic re-
modeling after TEVAR for acute aortic dissection. Schoder
et al17 detailed 28 patients with acute type B AD treated
during a 5-year period in Europe. They divided the aorta
into three segments related to the area of stent graft cover-
age and found a significant decrease in the false lumen
diameter in the stented area without a change in the max-
imum aortic diameter.17 Several other series reported di-
ameter measurements at specific anatomic locations along
the aorta after TEVAR for acute type B AD. They showed
a significant reduction in false lumen diameter over time
and an increase in true lumen, with the greatest changes
noted along the proximal one-third of the aorta.16,34
Division of the aorta into specific sections was not
possible with the current cohort of patients because of the
constraints of the prospective trial; however, our findings of
continued false lumen shrinkage with true lumen expansion
support the notion of early aortic remodeling after TEVAR.
There is currently no consensus regarding the best way
to measure or report aortic changes after TEVAR. Al-
though many studies, including this one, have used maxi-
mal aortic diameters because they are the most relevant to
clinical decision making, others have argued that volumet-
ric measurements are a more accurate way to characterize
aortic remodeling. Czermak et al35 have published several
reports of TEVAR for acute type B AD that describe
changes in true and false lumen volumes over time at
specific locations along the aorta. They found that the true
lumen volume significantly increased (nearly 59%) 12
months, whereas the false lumen volume significantly de-
creased over time. They also noted that length of stent
graft, percentage of stented dissection length, and origin of
visceral vessels did not predict changes in these vol-
umes.35,36 Whether diameter or volumetric measurements
are the most accurate way to describe aortic remodeling
remains to be seen and will likely be the topic of future
study.
This study has several limitations. The addition of our
single-center experience to the prospective, controlled trial
data could inject bias into the results because 50% of the
patients are now from a single institution. In addition,
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report, we were unable to relate demographic and treat-
ment factors to follow-up measurements, so that no
predictors of remodeling could be evaluated. Finally, the
follow-up period is short for the evaluation of aneurys-
mal degeneration, and longer studies will confirm dura-
bility of our early results.
CONCLUSIONS
The use of TEVAR in the treatment of aortic dissec-
tions holds promise to reduce both early complications and
the progression over time to aneurysmal degeneration by
early aortic remodeling. The instantaneous and dramatic
occurrence of false lumen thrombosis by coverage of the
aortic entry tear appears to be a key determinant in the
process; the significance of small distal fenestrations re-
mains unknown. These results support the notion that
comparative clinical trials are needed to clarify the role of
TEVAR in both complicated and uncomplicated acute
distal dissections.
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